Editorial policy for BioRadar analyses

This page covers BioRadar’s analyses: the in-depth articles on individual companies, drugs and FDA decisions in our Biotech Analysis section. It explains what they will and will not do, how we research them and how BioRadar makes money. Our automated data pages, screens and alerts are described on their own pages.

A neutral line

• No buy or sell calls. Our analyses do not tell you to buy, sell or hold a stock, and they carry no price targets or ratings.
• No bull or bear side. Each analysis sets out what the evidence supports and where it falls short, and where investors disagree, it presents the arguments on both sides. Its conclusion is about the evidence, not about whether to own the stock.
• Scenarios without odds. When we sketch scenarios, we describe what would have to happen and what to look for, and we do not assign probabilities. When an analysis quotes the approval-probability score from BioRadar’s PDUFA calendar, it shows how the model built that score.

No paid content

• Our analyses are never paid for, sponsored or written as advertising.
• Companies cannot pay for an analysis, choose its topic or change its content, and they do not see it before publication.
• We do not accept payments, shares or gifts from the companies we analyze.
• Our analyses contain no affiliate links. They link only to their sources and to other BioRadar pages.

How BioRadar makes money

BioRadar is paid for by subscriptions to its alerts, watchlists and data tools. Our analyses are free to read, and no one pays for them to be written. BioRadar does not show ads at present; if we add them, they will be clearly marked and kept apart from the text of our analyses.

Who writes them, and the author’s own positions

BioRadar is an independent site based in Finland. Our analyses are written and edited by Juha O. We are not a broker, a bank or a licensed investment adviser.

• Since October 15, 2026, each analysis ends by saying whether the author held shares in the company analyzed when it was written, for example: “The author held no IBRX shares when this was written.”
• The author does not buy or sell shares of a company from three trading days before to three trading days after publishing an analysis of it.

How we research an analysis

• Primary sources first: SEC filings, FDA and EMA documents (approval notices, labels, reviews, warning letters), ClinicalTrials.gov, peer-reviewed papers, Medicare (CMS) data and company press releases.
• Who says what: we keep apart what a regulator found, what a peer-reviewed paper reports and what a company says about its own data, and we label company figures as company figures.
• Checked before publication: every number, date and quote is checked against its source. Our own calculations are marked “our arithmetic”, with the inputs shown so readers can redo them.
• Estimates are scenarios: market sizes and similar estimates are labeled as illustrations built on stated assumptions, not as forecasts.
• Sources listed: each analysis ends with its sources, linked, and the date we read them.

How we use AI

AI tools, currently Anthropic’s Claude models, help us gather sources, check figures and draft text. Every analysis is reviewed and approved by the editor before it is published, and its factual claims are checked against the primary sources it cites.

Corrections and updates

If you find an error in an analysis, please email signals@bioradar.io. We correct factual errors promptly. When a correction changes a number, a quote or a conclusion, we add a dated note to the analysis saying what changed. When an analysis depends on a coming event, such as an FDA decision or a trial readout, it says so, and subscribers can follow those checkpoints in the analysis’s live tracker.

Not investment advice

Our analyses are general information, not personal investment advice. Biotech stocks can lose most of their value on a single event. Do your own research, and consider professional advice before making investment decisions.

Last updated: October 16, 2026